BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

Opublikowano 7 years temu: 17 June 2014 samochody.no Przeczytasz w: 1 minuta

17-06-2014 13:58 CEST Biogen Idec Norway AS ? DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate ? ? Positive Results Set Stage for Regulatory Filings

17-06-2014 13:58 CEST Biogen Idec Norway AS ? DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate ? ? Positive Results Set Stage for Regulatory Filings ?

Bezpośredni link:
BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS https://www.samochody.no/biogen-idec-and-abbvie-announce-positive-top-line-results-from-phase-3-study-investigating-daclizumab-high-yield-process-in-multiple-sclerosis